304 related articles for article (PubMed ID: 26799344)
1. Fifty years of pharmacovigilance - Medicines safety and public health.
Laporte JR
Pharmacoepidemiol Drug Saf; 2016 Jun; 25(6):725-32. PubMed ID: 26799344
[No Abstract] [Full Text] [Related]
2. Pharmacovigilance in Europe.
Johnson CL; Hutchinson JA
Transplantation; 2015 Aug; 99(8):1542-3. PubMed ID: 26308299
[No Abstract] [Full Text] [Related]
3. Towards Drug Safety Surveillance and Pharmacovigilance: Current Progress in Detecting Medication and Adverse Drug Events from Electronic Health Records.
Liu F; Jagannatha A; Yu H
Drug Saf; 2019 Jan; 42(1):95-97. PubMed ID: 30649734
[No Abstract] [Full Text] [Related]
4. Encouraging spontaneous reporting of adverse effects.
Prescrire Int; 2015 Feb; 24(157):53. PubMed ID: 25802925
[TBL] [Abstract][Full Text] [Related]
5. Report of Adverse Events in Colombia: A Successful Case.
Moreno-Mattar O; Ramírez R; Alvarado A; Sierra F; Guzmán J
Curr Drug Saf; 2019; 14(1):53-56. PubMed ID: 30411692
[TBL] [Abstract][Full Text] [Related]
6. Pharmacovigilance Programme of India: Recent developments and future perspectives.
Kalaiselvan V; Thota P; Singh GN
Indian J Pharmacol; 2016; 48(6):624-628. PubMed ID: 28066097
[TBL] [Abstract][Full Text] [Related]
7. [Adverse drug reaction - Definitions, risk factors and pharmacovigilance].
Krähenbühl S
Ther Umsch; 2015 Dec; 72(11-12):669-71. PubMed ID: 26654809
[TBL] [Abstract][Full Text] [Related]
8. [Editorial: adverse drug reactions].
Taegtmeyer AB
Ther Umsch; 2015 Dec; 72(11-12):667. PubMed ID: 26654808
[No Abstract] [Full Text] [Related]
9. Under-reporting of adverse drug reactions: a challenge for pharmacovigilance in India.
Tandon VR; Mahajan V; Khajuria V; Gillani Z
Indian J Pharmacol; 2015; 47(1):65-71. PubMed ID: 25821314
[TBL] [Abstract][Full Text] [Related]
10. Current trends in pharmacovigilance: value and gaps of patient reporting.
Inácio P; Cavaco A; Airaksinen M
Int J Clin Pharm; 2018 Aug; 40(4):754-757. PubMed ID: 30006734
[No Abstract] [Full Text] [Related]
11. Pharmacovigilance: Importance, concepts, and processes.
Kumar A
Am J Health Syst Pharm; 2017 Apr; 74(8):606-612. PubMed ID: 28235869
[No Abstract] [Full Text] [Related]
12. The reorganisation of European pharmacovigilance. Part 2. From spontaneous reports to agency reviews and decisions.
Prescrire Int; 2015 Feb; 24(157):50-4. PubMed ID: 25802924
[TBL] [Abstract][Full Text] [Related]
13. Fifteen years of patient reporting -what have we learned and where are we heading to?
van Hunsel F; Härmark L; Rolfes L
Expert Opin Drug Saf; 2019 Jun; 18(6):477-484. PubMed ID: 31030578
[TBL] [Abstract][Full Text] [Related]
14. French pharmacovigilance: Missions, organization and perspectives.
Vial T
Therapie; 2016 Apr; 71(2):143-50. PubMed ID: 27080832
[TBL] [Abstract][Full Text] [Related]
15. Promoting and Protecting Public Health: How the European Union Pharmacovigilance System Works.
Santoro A; Genov G; Spooner A; Raine J; Arlett P
Drug Saf; 2017 Oct; 40(10):855-869. PubMed ID: 28735357
[TBL] [Abstract][Full Text] [Related]
16. Pharmacovigilance workflow in Europe and Italy and pharmacovigilance terminology.
Baldo P; Francescon S; Fornasier G
Int J Clin Pharm; 2018 Aug; 40(4):748-753. PubMed ID: 30094557
[TBL] [Abstract][Full Text] [Related]
17. Intensive safety monitoring program of antineoplastic medicines: A pilot study in a Portuguese oncology hospital.
Mendes D; Rigueiro G; Silva RS; Penedones A; Alves C; Sousa G; Batel-Marques F
J Oncol Pharm Pract; 2020 Jan; 26(1):133-140. PubMed ID: 31117914
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
[TBL] [Abstract][Full Text] [Related]
19. Surveillance of Drug Safety During Pregnancy: Insight in Current International Activities, Future Intentions and Need for Support of National Pharmacovigilance Centres.
Kant A; de Vries L; Rolfes L
Drug Saf; 2019 Jan; 42(1):35-43. PubMed ID: 30284215
[TBL] [Abstract][Full Text] [Related]
20. The contribution of direct patient reported ADRs to drug safety signals in the Netherlands from 2010 to 2015.
van Hunsel F; de Waal S; Härmark L
Pharmacoepidemiol Drug Saf; 2017 Aug; 26(8):977-983. PubMed ID: 28524293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
